BioMimetic Therapeutics, Inc. (BMTI) Posts Wider than Expected Q4 Loss
Tweet
Share
E-mailGet Alerts BMTI Hot Sheet
Price: $9.49 --0%
Financial Fact:
Depreciation and capital lease amortization: 233.35K
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Depreciation and capital lease amortization: 233.35K
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) reported Q4 EPS of ($0.35), $0.09 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $458 thousand versus the consensus estimate of $310 thousand.
For earnings history and earnings-related data on BioMimetic Therapeutics, Inc. (BMTI) click here.
For earnings history and earnings-related data on BioMimetic Therapeutics, Inc. (BMTI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance
- OMNIQ Corp. posts Q2 2026 revenue of $7.4M, widens net loss
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
